Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study.
Authors
Leijuan Gan
Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin’s Clinical Research Center for Cancer, Tianjin, China;
Leijuan Gan , Huikai Li , Qiang Wu , Qiang Li , Yunlong Cui , Wei Zhang , Feng Fang , Wei Lu , Guangtao Li , Shaohua Ren , Yayue Liu , Mengran Lang , Ruyu Han , Tianqiang Song
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 544)
DOI
10.1200/JCO.2023.41.4_suppl.544
Abstract #
544
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma who previously received systemic treatment.
First Author: Takeshi Terashima
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
First Author: Alina Pascale
Poster
2023 ASCO Annual Meeting
Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.
First Author: Ming Liu
Poster
2020 ASCO Virtual Scientific Program
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
First Author: Arndt Vogel